Ansa Biotechnologies

🧬 How far can your DNA take you? For most teams, the answer is still constrained by what can actually be built. At Ansa, we’ve removed that limitation so you can design to the needs of biology, not the constraints of your typical DNA provider. 👉 ansabio.com

Jason T. Gammack said @AnsaBio shipped 47 megabases of DNA, about 26,000 genes, with a 97.3% fulfillment rate as it expands clonal DNA up to 50 kb through @idtdna. #SynBioBeta #Biotech

@johncumbers @Jason_Gammack @AnsaBio @SynBioBeta 50kb perfect constructs change what I dare to design. When synthesis becomes reliable infrastructure rather than a bottleneck, I stop working around supplier limitations and start building the biology I actually want.

"The constraints we've been taught to accept are not laws of nature—they're artifacts of legacy manufacturing.” Ansa CEO @Jason_Gammack gives his perspective ahead of #SynBioBeta. 👉 bit.ly/3Qxk2VJ

@idtdna We look forward to being side-by-side booth buddies too!

We’re excited to return to SynBioBeta 2026! 🎉 Join IDT experts at booth #308 to explore what’s possible with a complete #syntheticbiology portfolio—designed for speed, scale, and partnership. Chris Vakulskas, senior director of enzyme development, will present on two panel discussions with our partner, @AnsaBio. Details are below—we look forward to welcoming you! 1️⃣Breaking the barriers of DNA synthesis: Shattering the ceiling? 📅May 5 | 3:30–4:15 p.m. 🧬Explore how new enzymatic synthesis platforms and assembly approaches are pushing past long standing limits—enabling faster, larger, and more complex DNA designs at scale. 2️⃣Skip the assembly, go straight to your next breakthrough: How innovative DNA synthesis Is changing what's possible in biopharma. 📅May 6 | 3:30–4:15 p.m. 🧬A look at how reliable, on time access to long and complex synthetic DNA is reshaping build vs buy decisions and accelerating design–build–test–learn cycles in biopharma. 🔗Learn more here: syntheticbiologysummit.com

We can read DNA. We can design DNA. But building it? Still one of the biggest bottlenecks in biology. To mark #DNADay, we're sharing a chat with Ansa CEO @Jason_Gammack about where the field is going: ansabio.com/resources/vide…

As we reflect on #sustainability in science this #EarthDay, there’s an uncomfortable question worth asking: Why does the foundation of synthetic biology still rely on processes that generate so much waste? We believe there's a better way. Learn more: ansabio.com/technology/

AI design algorithms are generating more ambitious DNA constructs than legacy synthesis can handle. High GC content, repetitive sequences, long constructs that require assembly and cloning work that takes weeks in the lab. That's the bottleneck. @AnsaBio is attacking it with enzymatic synthesis: no harsh chemicals, no damage to the growing molecule, direct synthesis of sequences up to 1,005 bases (a world record) assembled into constructs up to 50 kb, delivered in under four weeks. @Jason_Gammack presents at @SynBioBeta 2026 with real-world data on where enzymatic synthesis outperforms legacy methods and what it actually changes about the build vs. buy decision for complex DNA. SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=X&…

After 20+ years in DNA synthesis, Ansa’s new COO Matthias Arenskötter shares why the field needs a new approach, and how long, reliable DNA unlocks real design freedom. 📖 linkedin.com/pulse/after-tw…

We’re excited to welcome Matthias Arenskötter as Ansa’s new COO. With 20+ years in DNA synthesis and deep expertise in scaling advanced manufacturing, Matthias will lead global ops as we meet rising demand for long, complex DNA. 🔗bit.ly/4tgt2fE

#Biosecurity isn’t a ‘nice to have’ in DNA synthesis. It’s a core responsibility. We screen & verify every DNA order before manufacturing begins, w/ automated sequence checks, expert review & strong data security to protect sensitive designs. 👉 hubs.li/Q04869W-0

The biggest limitation in DNA synthesis isn’t cost. It’s: • Sequence rejection • Unpredictable timelines Accessing complex DNA is only half the problem. Getting it when you expect it is what keeps science moving. 📑 Read the Tech Note here: hubs.li/Q047n2hW0

Behind every shipment is a team committed to getting it right. This is the final step before orders ship under the Ansa On-Time Guarantee—helping scientists receive sequence-verified clonal DNA reliably and on schedule.

📣 Our team is excited to share that our synthetic DNA contributed to a new study in @Nature led by @arcinstitute introducing the Evo 2 genomic foundation model. 📑 Read the paper: lnkd.in/gxJS8rSJ

@BrianHie @pdhsu @Nature This would not have been possible without @AnsaBio providing the synthetic DNA. Their up to 50kb clonal DNA without any sequence restrictions is an absolute game changer!

@AnsaBio Design to delivery at speed. 🧬⚡ Synthesizing a 23 kb dystrophin plasmid in just 20 business days and pairing it with AI‑guided delivery shows how complex DNA can move rapidly from concept to application. A glimpse of the future of precision biotech.

🧭 We didn’t set out to reinvent DNA synthesis. We set out to solve a problem we experienced ourselves. Want to understand the science behind Ansa’s approach, and why enzymatic synthesis changes what’s possible? Read on: ansabio.com/blog/ansas-enz…

How fast can large, complex DNA move from design to delivery? This on-demand webinar breaks down a 23 kb dystrophin plasmid synthesized in 20 business days, and used immediately with AI-guided delivery vehicles. Watch here 👉 hubs.li/Q03Vg1SR0 #GeneTherapy #GeneSynthesis

Drug Discovery News highlights an advance from New England Bio Labs and Yale University: a synthetic phage engineering platform that enables phages to be designed and built entirely in the lab. Proud that Ansa could deliver the DNA for this study. 🔗 drugdiscoverynews.com/new-synthetic-…

ICYMI: Last week’s #JPM event sponsored by Mithrl was a packed house with sharp insights on the future of AI in biology. Leaders across pharma, biotech & AI, including Jason T. Gammack, shared what will drive the next era of therapeutic discovery. 👉 ansabio.com